The study is a 17-week, single-center, double-blind, parallel-group, randomized placebo
controlled trial that will test the efficacy of liraglutide 3.0 mg/d as compared to placebo
in reducing the number of binge episodes per week, achieving remission from binge episodes,
and in changes in body weight, global BED symptom improvement, cognitive restraint of food
intake, dietary disinhibition, perceived hunger, quality of life, and depressed mood at
treatment end.